Kabra Drugs
BSE: KABRADG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kabra Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kabra Drugs Limited is an Indore-based company engaged in the manufacturing, marketing, and distribution of pharmaceutical formulations and bulk drugs. The firm also operates in the chemical sector, focusing on the trading of industrial chemicals and various commodities to diversify its revenue base.
Business Model
The company generates revenue through the production of medicinal products and the trading of industrial chemicals. It functions as a niche participant within the regional pharmaceutical distribution network.
Growth Outlook
Growth is primarily driven by the company's efforts to diversify its revenue streams through the trading of various commodities and chemicals. Its position as a micro-cap entity allows for potential agility in regional market segments.
Key Risks
- Regulatory Risk. The pharmaceutical industry is subject to stringent government regulations and quality control standards that can impact operational costs.
- Market Competition. As a micro-cap entity, the company faces intense competition from larger, better-capitalised pharmaceutical firms with greater economies of scale.
- Commodity Price Volatility. The company's reliance on chemical and commodity trading exposes it to fluctuations in global market prices and supply chain disruptions.
- Liquidity Risk. Being a micro-cap stock, the company may experience lower trading volumes, which can lead to higher price volatility for investors.
Start your research today
Unlock AI insights, financials, peers and live data on Kabra Drugs and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kabra DrugsKABRADG | ₹47 Cr | — | — | — | 5.8% | — | — | +7.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Kabra Drugs
BSE: KABRADG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kabra Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kabra Drugs Limited is an Indore-based company engaged in the manufacturing, marketing, and distribution of pharmaceutical formulations and bulk drugs. The firm also operates in the chemical sector, focusing on the trading of industrial chemicals and various commodities to diversify its revenue base.
Business Model
The company generates revenue through the production of medicinal products and the trading of industrial chemicals. It functions as a niche participant within the regional pharmaceutical distribution network.
Growth Outlook
Growth is primarily driven by the company's efforts to diversify its revenue streams through the trading of various commodities and chemicals. Its position as a micro-cap entity allows for potential agility in regional market segments.
Key Risks
- Regulatory Risk. The pharmaceutical industry is subject to stringent government regulations and quality control standards that can impact operational costs.
- Market Competition. As a micro-cap entity, the company faces intense competition from larger, better-capitalised pharmaceutical firms with greater economies of scale.
- Commodity Price Volatility. The company's reliance on chemical and commodity trading exposes it to fluctuations in global market prices and supply chain disruptions.
- Liquidity Risk. Being a micro-cap stock, the company may experience lower trading volumes, which can lead to higher price volatility for investors.
Start your research today
Unlock AI insights, financials, peers and live data on Kabra Drugs and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026